Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (121-130 of 301) with videos related to

Pageof 31
Sort By:
Pharmacoeconomics|June 20, 2019
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Health Affairs (Project Hope)|January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologistsPeter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Health Affairs (Project Hope)|November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 PandemicPeter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health|March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Pharmacoeconomics - Open|July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness EstimatesRachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine|October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic ReviewAaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literaturePei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY StudiesAshley A Leech, David D Kim, Joshua T Cohen, et al.
American Journal of Public Health|September 16, 2016
Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority AreasPeter J Neumann, Megan Farquhar, Colby L Wilkinson, et al.
Pageof 31

Showing results (121-130 of 301) with videos related to

Sort By:
Pageof 31
Pharmacoeconomics|June 20, 2019
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Health Affairs (Project Hope)|January 6, 2010
Cancer therapy costs influence treatment: a national survey of oncologistsPeter J Neumann, Jennifer A Palmer, Eric Nadler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
Health Affairs (Project Hope)|November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 PandemicPeter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health|March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Pharmacoeconomics - Open|July 23, 2022
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness EstimatesRachel Milstein Breslau, Joshua T Cohen, Daniel A Ollendorf, et al.
American Journal of Preventive Medicine|October 17, 2015
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic ReviewAaron N Winn, Donatus U Ekwueme, Gery P Guy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Willingness to pay for diagnostic technologies: a review of the contingent valuation literaturePei-Jung Lin, Michael J Cangelosi, David W Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY StudiesAshley A Leech, David D Kim, Joshua T Cohen, et al.
American Journal of Public Health|September 16, 2016
Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority AreasPeter J Neumann, Megan Farquhar, Colby L Wilkinson, et al.
Pageof 31